The point about sales rep evaluation is particularly interesting. Do you think these changes drove improved financial results, or did financial performance improve despite these changes to sales rep compensation? If the former, do you think this model of sales rep compensation is transferable to other pharma companies or are there reasons you think it could only work at GSK?
You mentioned that patients using Teladoc are “encouraged” to update their records with their primary physician after their Teladoc appointment. How realistic do you think it is that patients will actually do this proactively? Is there any way you could imagine Teladoc taking care of this for patients automatically?
How would you assess Goodell’s performance, both in light of the controversies you’ve mentioned but also the league’s strong financial performance?